News & Articles

The antigen test is used to detect the nucleocapsid protein antigen in SARS-CoV-2

Seegene can produce 300,000 variant diagnostic test kits, capable of testing 30 million people every month

Highly complementary cell counting and analysis capabilities bolster preclinical portfolio and enhance QA/QC capabilities in cell and gene therapy and biologics manufacturing

The Simplexa™ SARS-CoV-2 Variants Direct assay aims to enable detection of four mutations associated with virus variants without requiring upfront RNA extraction

The availability of an International Standard (IS) for antibodies facilitates the standardization of SARS-CoV-2 serological methods

Platform poised to be first CLIA-waived CRISPR-based, point-of-care COVID-19 device with central-lab performance, developed in collaboration with Sherlock Biosciences

For a chance to win a $500/£400/450€ Amazon Gift Card, cast your vote for the new products which have made the most difference to clinical diagnostics

In a Phase 3 trial, the vaccine was 100% effective and generally well tolerated in participants aged 12 to 15 years

Discover how collaborative research between big pharma and academia is using the latest proteomics platforms to revolutionize drug discovery

KSQ Therapeutics uses technology created at MIT to study the role of every human gene in disease biology

New, reversible CRISPR method can control gene expression while leaving underlying DNA sequence unchanged

Vaccine, trialed in 450 children, shows favorable safety profile and was well-tolerated

COVID-19 infections fell by 65% percent after a first dose of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines in this large community surveillance study

A new Prenetics Innovation Technology Centre will be established for advanced molecular diagnostics

Anti-cancer drug delivery to target tumor sites now becomes more effective with novel multi-stimuli-responsive drug delivery systems

An insider’s view on leveraging the latest single-cell technologies, including cell sorting and single-cell sequencing, to understand what drives response or resistance in checkpoint therapies

Dr. Tania Nolan outlines how her team is designing assays to identify new variants and why these are critical to managing the global response

Each line of ValuPanel Reagents consists of separately delivered probes and primers, which allow assay flexibility and sizes that can help facilitate scale-up